DOCSLIB.ORG

Diuretics for Hypertension: Hydrochlorothiazide Or Chlorthalidone?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diuretics for Hypertension: Hydrochlorothiazide Or Chlorthalidone? REVIEW CME EDUCATIONAL OBJECTIVE: Readers will summarize the similarities and differences between hydrochlorothiazide CREDIT and chlorthalidone DANIELLE COONEY, PharmD SHERRY MILFRED-LaFOREST, PharmD MAHBOOB RAHMAN, MD, MS Louis Stokes Cleveland VA Medical Center, Louis Stokes Cleveland VA Medical Center, Louis Stokes Cleveland VA Medical Center; Cleveland, OH Cleveland, OH University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH Diuretics for hypertension: Hydrochlorothiazide or chlorthalidone? ABSTRACT he thiazide diuretic hydrochlorothia- T zide and the thiazidelike diuretic chlortha- Thiazide diuretics are the cornerstone of treatment of lidone are two old drugs that are still useful. hypertension in most patients. Hydrochlorothiazide is Although similar, they differ in important ways the most commonly used thiazide diuretic in the United still not fully appreciated more than a half cen- States, but interest in chlorthalidone is increasing. The tury after they were introduced. authors summarize the literature comparing these two Most hypertension guidelines recommend agents. thiazide diuretics as one of the classes of agents that can be used either as initial antihyperten- KEY POINTS sive drug therapy or as part of combination therapy.1–3 Chlorthalidone has a longer duration of action and a In the United States, hydrochlorothiazide longer half-life than hydrochlorothiazide. is used more often than chlorthalidone, but many clinical trials of antihypertensive thera- Chlorthalidone may be more potent than hydrochloro- py have used chlorthalidone.4,5 In recent years, thiazide in lowering blood pressure, but it also may be particularly after the publication of the Anti- associated with more metabolic adverse effects, such as hypertensive and Lipid-Lowering Treatment hypokalemia. to Prevent Heart Attack Trial (ALLHAT), interest in chlorthalidone has been increasing, and new data are now available comparing No study has conclusively shown either drug to be better these two diuretics.6 While current US guide- in preventing adverse clinical outcomes. lines do not recommend one over the other, British guidelines prefer chlorthalidone.7 These differences should be considered when making This review summarizes the data comparing choices about thiazide diuretic therapy for hypertension. the two drugs’ pharmacology, antihypertensive effect, and impact on clinical outcomes to help guide clinicians in choosing antihypertensive drug therapy. ■ PHARMACOLOGY AND MECHANISM OF ACTION Many of the differences in effectiveness and ad- verse effects of hydrochlorothiazide and chlortha- lidone are thought to be due to their different pharmacodynamic and pharmacokinetic effects. Pharmacodynamic effects Hydrochlorothiazide and chlorthalidone differ doi:10.3949/ccjm.82a.14091 significantly in chemical structure (Figure 1), CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 82 • NUMBER 8 AUGUST 2015 527 HYDROCHLOROTHIAZIDE AND CHLORTHALIDONE Hydrochlorothiazide inhibition of carbonic anhydrase than hydro- chlorothiazide, which can lead to lower intra- H cellular pH and cell volume. This effect may in Cl N part explain a pleiotropic effect of chlorthali- done, ie, inhibition of platelet function, which in turn may contribute to this drug’s beneficial 9 H2N NH effect on cardiovascular outcomes. Sulfonamide SSPharmacokinetic differences group Hydrochlorothiazide and chlorthalidone have O OO O important differences in their pharmacokinet- ic properties (Table 1).11 Chlorthalidone Hydrochlorothiazide has its onset of action Cl in about 2 hours, and it reaches its peak in 4 to 6 hours. Though its duration of action is OH short—up to 12 hours—its pharmacodynamic H2N response can be much longer than predicted Sulfonamide S by its kinetics, allowing once-daily dosing.8 group Chlorthalidone has a longer duration of O O HN action than hydrochlorothiazide. This may be because it has a very high volume of distribu- tion, since it is taken up into red blood cells O and is bound to carbonic anhydrase.12 This FIGURE 1. Although the chemical structures may result in a “drug reservoir” that keeps drug of hydrochlorothiazide (top) and chlortha- levels higher for a longer time.13 Its long dura- lidone (bottom) differ, they both contain a tion of action makes it a favorable choice for sulfonamide group that inhibits carbonic anhydrase activity. This action may be asso- patients who have difficulty adhering to medi- A pleiotropic ciated with lower vascular contractility. cation instructions. In addition, a missed dose is unlikely to have a “rebound” effect like that effect of but both contain a sulfonamide group that in- seen with some other antihypertensive agents. chlorthalidone: hibits carbonic anhydrase activity, which may However, both chlorthalidone and hydrochlo- inhibition be associated with lower vascular contractility. rothiazide are effective if taken once daily. Both drugs are concentrated in the kidney and of platelet secreted into the tubular lumen8; therefore, their ■ BLOOD PRESSURE-LOWERING function therapeutic diuretic effects are often achieved Both hydrochlorothiazide and chlorthalidone with relatively low plasma concentrations. are effective antihypertensive agents. Table 2 Both drugs inhibit the sodium-chloride co- summarizes findings from studies that evaluat- transporter in the luminal membrane of the ed their blood pressure-lowering effect at vari- distal convoluted tubule of the ascending loop ous doses.14–33 However, relatively few studies of Henle, leading to a modest natriuresis and have directly compared these two agents’ ef- diuresis. The exact mechanism by which they fects on blood pressure. lower blood pressure is not known: while the Ernst et al,34 in a small study (but probably initial response is from diuresis and volume the best one to address this issue), compared changes, long-term reduction in blood pressure chlorthalidone 12.5 mg/day (force-titrated to is through uncertain mechanisms. In addition, 25 mg/day) and hydrochlorothiazide 25 mg/day chlorthalidone may have beneficial effects on (force-titrated to 50 mg/day) in untreated hy- endothelial function and oxidative stress.9,10 pertensive patients. After 8 weeks, ambulatory Both drugs also increase secretion of potas- blood pressure monitoring indicated a greater sium and hydrogen ions and promote increased reduction from baseline in systolic blood pres- reabsorption of calcium through increased sure with chlorthalidone 25 mg/day than with expression of a sodium-calcium exchange hydrochlorothiazide 50 mg/day (24-hour mean channel.8 Chlorthalidone may cause more –12.4 vs –7.4 mm Hg, P = .05). Interestingly, 528 CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 82 • NUMBER 8 AUGUST 2015 COONEY AND COLLEAGUES the change in nighttime blood pressure was greater in the chlorthalidone group (–13.5 mm TABLE 1 Hg) than in the hydrochlorothiazide group Pharmacokinetics and pharmacodynamics (–6.4 mm Hg; P = .009). These data suggest of hydrochlorothiazide and chlorthalidone that at the doses studied, chlorthalidone is more effective than hydrochlorothiazide in Hydrochlorothiazide Chlorthalidone lowering systolic blood pressure. Onset 2 hours 2.6 hours Bakris et al,35 using a different study de- sign, compared the single-pill combination of Peak effect 4–6 hours 1.5–6 hours azilsartan medoxomil and chlorthalidone vs Absorption Well absorbed a 65% coadministration of azilsartan medoxomil and hydrochlorothiazide in participants with stage Duration 6–12 hours 48–72 hours 2 primary hypertension (≥ 160/100 mm Hg). Protein binding 40%–68% 75% Systolic blood pressure, as measured in the clinic, declined more with the chlorthalidone Metabolism Not metabolized Hepatic combination (–35.1 mm Hg) than with the b hydrochlorothiazide combination (–29.5 mm Elimination half-life 10–12 hours 40–89 hours Hg, mean difference –5.6 mm Hg, P < .001). Excretion pathway Urine (as unchanged Urine c Meta-analyses also support the conclu- drug) sion that chlorthalidone is more potent than a When taken with food, time to maximum concentration increases from 1.6 hours to hydrochlorothiazide in lowering blood pres- 2.9 hours. Absorption is reduced in patients with chronic heart failure. sure.35,36 Several studies have shown that b Large variation due to biphasic elimination; may be much longer with renal impair- chlorthalidone at the same dose is 1.5 to 2 ment. times as potent as hydrochlorothiazide.33,36,37 c Data not available on the percentage of dose as unchanged drug and metabolites, concentration of the drug in body fluids, degree of uptake by a particular organ or in Therefore, for clinical purposes, it is reason- the fetus, or passage across the blood-brain barrier. able to consider chlorthalidone 12.5 mg daily Information from US National Library of Medicine. Dailymed. dailymed.nlm.nih.gov. as similar to 25 mg of hydrochlorothiazide Accessed May 31, 2015. daily. ■ ADVERSE EFFECTS unless the dose is increased, extrarenal losses of potassium increase, or dietary potassium is Electrolyte disturbances are a common ad- reduced. verse effect of thiazide diuretics. Other electrolyte changes. Thiazide and Hypokalemia. All thiazide diuretics cause thiazide-like diuretics can cause other meta- potassium wasting. The frequency of hypoka- bolic and endocrine abnormalities such as lemia depends on the dose, frequency of ad- ministration, diet, and other pharmacologic hypochloremic alkalosis, hyponatremia, and hypercalcemia.40,41 They can also cause photo- agents used. 42 Two large clinical trials, the
Load more

Recommended publications
  • Pediatric Pharmacotherapy
    Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 1, Number 10, October 1995 DIURETICS IN CHILDREN • Overview • Loop Diuretics • Thiazide Diuretics • Metolazone • Potassium Sparing Diuretics • Diuretic Dosages • Efficacy of Diuretics in Chronic Pulmonary Disease • Summary • References Pharmacology Literature Reviews • Ibuprofen Overdosage • Predicting Creatinine Clearance Formulary Update Diuretics are used for a wide variety of conditions in infancy and childhood, including the management of pulmonary diseases such as respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD)(1 -5). Both RDS and BPD are often associated with underlying pulmonary edema and clinical improvement has been documented with diuretic use.6 Diuretics also play a major role in the management of congestive heart failure (CHF), which is frequently the result of congenital heart disease (7). Other indications, include hypertension due to the presence of cardiac or renal dysfunction. Hypertension in children is often resistant to therapy, requiring the use of multidrug regimens for optimal blood pressure control (8). Control of fluid and electrolyte status in the pediatric population remains a therapeutic challenge due to the profound effects of age and development on renal function. Although diuretics have been used extensively in infants and children, few controlled studies have been conducted to define the pharmacokinetics and pharmacodynamics of diuretics in this population. Nonetheless, diuretic therapy has become an important part of the management of critically ill infants and children. This issue will review the mechanisms of action, monitoring parameters, and indications for use of diuretics in the pediatric population (1-5). Loop Diuretics Loop diuretics are the most potent of the available diuretics (4).
    [Show full text]
  • High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 5-2010 High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity Albert A. Barrese III Western Michigan University Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Biochemistry, Biophysics, and Structural Biology Commons, and the Biology Commons Recommended Citation Barrese, Albert A. III, "High-Throughput Screening Studies of Inhibition of Human Carbonic Anhydrase II and Bacterial Flagella Antimicrobial Activity" (2010). Dissertations. 500. https://scholarworks.wmich.edu/dissertations/500 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. HIGH-THROUGHPUT SCREENING STUDIES OF INHIBITION OF HUMAN CARBONIC ANHYDRASE II AND BACTERIAL FLAGELLA ANTIMICROBIAL ACTIVITY by Albert A. Barrese III A Dissertation Submitted to the Faculty of The Graduate College in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Department of Biological Sciences Advisor: Brian C. Tripp, Ph.D. Western Michigan University Kalamazoo, Michigan May 2010 UMI Number: 3410393 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. UMT Dissertation Publishing UMI 3410393 Copyright 2010 by ProQuest LLC.
    [Show full text]
  • Drugs and Life-Threatening Ventricular Arrhythmia Risk: Results from the DARE Study Cohort
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2017-016627 on 16 October 2017. Downloaded from Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort Abigail L Coughtrie,1,2 Elijah R Behr,3,4 Deborah Layton,1,2 Vanessa Marshall,1 A John Camm,3,4,5 Saad A W Shakir1,2 To cite: Coughtrie AL, Behr ER, ABSTRACT Strengths and limitations of this study Layton D, et al. Drugs and Objectives To establish a unique sample of proarrhythmia life-threatening ventricular cases, determine the characteristics of cases and estimate ► The Drug-induced Arrhythmia Risk Evaluation study arrhythmia risk: results from the the contribution of individual drugs to the incidence of DARE study cohort. BMJ Open has allowed the development of a cohort of cases of proarrhythmia within these cases. 2017;7:e016627. doi:10.1136/ proarrhythmia. Setting Suspected proarrhythmia cases were referred bmjopen-2017-016627 ► These cases have provided crucial safety by cardiologists across England between 2003 and 2011. information, as well as underlying clinical and ► Prepublication history for Information on demography, symptoms, prior medical and genetic data. this paper is available online. drug histories and data from hospital notes were collected. ► Only patients who did not die as a result of the To view these files please visit Participants Two expert cardiologists reviewed data the journal online (http:// dx. doi. proarrhythmia could be included. for 293 referred cases: 130 were included. Inclusion org/ 10. 1136/ bmjopen- 2017- ► Referral of cases by cardiologists alone may have criteria were new onset or exacerbation of pre-existing 016627).
    [Show full text]
  • Guidelines for the Management of Hyponatraemia in Hospitalised Patients
    Guidelines for the management of hyponatraemia in hospitalised patients Authors: V Mishra Aims: To provide guidelines for appropriate investigations and treatment of hyponatraemia in hospitalised patients. Normal range Mild Moderate hyponatraemia Severe hyponatraemia hyponatraemia 135-146 mmol/L 130-135 mmol/L 120-129 mmol/L <120 mmol/L Evaluation of hyponatraemia STEP 1: Rule out artefactual causes Is the patient on IV fluids? If so, could the sample have been taken “downstream” from the infusion site? Could the sample have been taken from the same line? STEP 2: Clinical history Check fluid balance to exclude fluid overload Is the patient diabetic? Hyperglycemia may cause dilutional hyponatraemia and increased urinary loss of sodium Correct serum sodium for hyperglycemia (rise in plasma glucose >5.5mmol/L) by using equation given in (Appendix 1) Consider medications (Table 1). In some cases, stopping the medication or changing to an alternative that does not cause hyponatraemia may be sufficient. Monitor sodium concentrations to assess the effects of this management. It may take several days for the sodium to normalise after withdrawing medications Review clinical history for relevant conditions (such as congestive cardiac failure, kidney disease, liver failure, lung pathology) Loss of weight /appetite: investigate for malignancy 1 Table 1: Drugs known to cause hyponatraemia Drug group Examples known to causecause hyponatraemia (other compounds may exist) TThiazidehiazide diuretics Bendroflumethiazide, Metolazone, Indapamide,
    [Show full text]
  • DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
    DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically.
    [Show full text]
  • Spironolactone Therapy in Infants with Congestive Heart Failure Secondary to Congenital Heart Disease
    Arch Dis Child: first published as 10.1136/adc.56.12.934 on 1 December 1981. Downloaded from Archives of Disease in Childhood, 1981, 56, 934-938 Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease SUSAN M HOBBINS, RODNEY S FOWLER, RICHARD D ROWE, AND ANDREW G KOREY Division of Cardiology, Department ofPaediatrics, Hospital for Sick Children, Toronto, and Department ofPaediatrics, University of Toronto, Canada SUMMARY The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age. All received digoxin and chlorothiazide. In addition, group A (n = 10) was given supplements of potassium and group B (n = 11) received spironolactone. Daily clinical observations of vital signs, weight, hepatomegaly, and vomiting were recorded. Paired t test analysis showed significant reduction in liver size and weight (P< 01) and respiratory rate (P< 0 05) in group B, and less significant decreases in group A. The incidence of vomiting was slightly lower in group B. We conclude that the addition of spiro- nolactone hastens and enhances the response to standard treatment with digoxin and chlorothiazide in infants with congestive heart failure. Spironolactone, a pharmacological antagonist of the We excluded or withdrew from the study any adrenal mineralocorticoid,l has been used for some infant in whom any of the following was present copyright. years in the treatment of congestive heart failure or developed. (1) Renal disease or dysfunction, as (CHF). By competitively binding to specific nuclear shown by blood urea nitrogen >8-925 mmol/l macromolecules in the distal convoluted renal (25 mg/100ml) or hepatic disease or dysfunction.
    [Show full text]
  • Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research
    Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Garabedian, Laura Faden. 2013. Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research. Doctoral dissertation, Harvard University. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11156786 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research A dissertation presented by Laura Faden Garabedian to The Committee on Higher Degrees in Health Policy in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Health Policy Harvard University Cambridge, Massachusetts March 2013 © 2013 – Laura Faden Garabedian All rights reserved. Professor Stephen Soumerai Laura Faden Garabedian Quasi-Experimental Health Policy Research: Evaluation of Universal Health Insurance and Methods for Comparative Effectiveness Research Abstract This dissertation consists of two empirical papers and one methods paper. The first two papers use quasi-experimental methods to evaluate the impact of universal health insurance reform in Massachusetts (MA) and Thailand and the third paper evaluates the validity of a quasi- experimental method used in comparative effectiveness research (CER). My first paper uses interrupted time series with data from IMS Health to evaluate the impact of Thailand’s universal health insurance and physician payment reform on utilization of medicines for three non-communicable diseases: cancer, cardiovascular disease and diabetes.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Patient Information Leaflet
    Package leaflet: Information for the patient Zornichka 12,5 mg tablets Zornichka 25 mg tablets Chlortalidone Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Zornichka is and what it is used for 2. What you need to know before you take Zornichka 3. How to take Zornichka 4. Possible side effects 5. How to store Zornichka 6. Contents of the pack and other information 1. What Zornichka is and what it is used for Zornichka belongs to a group of medicines called thiazide diuretics (“water tablets”). Thiazide diuretics help to reduce the amount of water in your body. They do this by increasing the amount of water that you pass as urine. Zornichka is used to: treat high blood pressure (hypertension) – as monotherapy or in combination with other antihypertensive (lowering high blood pressure) medicines. as an additional therapy for the treatment of edema caused by mild to moderate heart failure (II- III functional class); hepatic cirrhosis with ascites; corticosteroid and estrogen therapy, and some forms of impaired renal function (nephrotic syndrome, acute glomerulonephritis and chronic renal failure - creatinine clearance > 30 ml/min).
    [Show full text]
  • Choice of Medicines for Hypertension
    CORRESPONDENCE Hypertension guidelines versus individual studies: Should we hang our hat on ALLHAT? Recommendations in Best Practice Journal are tailored to the needs of primary care health professionals by incorporating information from guidelines, and where necessary, adapting this to a New Zealand context. Naturally, this guidance will sometimes differ from conclusions that are based on individual studies. “Hypertension in Adults: The silent killer”, BPJ 54 (Aug, 2013) was largely based on the United Kingdom National Choice of medicines for hypertension Institute of Health and Care Excellence (NICE) guidelines Dear Editor for the clinical management of primary hypertension in There were a few problems with the article: “Hypertension in adults (2011).1 The discrepancies highlighted between the adults: the silent killer”, BPJ 54 (Aug, 2013). I usually find the bpacnz recommendations in the Best Practice Journal article and the resources well written and evidence based. In this review there results of the Antihypertensive and Lipid Lowering Treatment were a number of key errors: to Prevent Heart Attack Trial (ALLHAT) represent differences in 1. Start with an ACE inhibitor or calcium channel blocker. clinical/expert opinion rather than “key errors”. Ironically there is data that neither of these medications are more effective than chlorthalidone – a thiazide-like diuretic: 1. We agree that the ALLHAT trial published in 2002 did see ALLHAT study, JAMA 2002;288:2981-97, which found, not show evidence of superiority for thiazide-like diuretics albeit for the secondary but important outcome of combined over ACE inhibitors or calcium channel blockers. ALLHAT cardiovascular disease, that chlorthalidone was more effective reported that all three medicines were equally effective in 2 than lisinopril and amlodipine.
    [Show full text]
  • Heart Failure — Managing Newly Diagnosed and Decompensated
    Clinical Guideline Heart failure: Managing newly diagnosed and decompensated patients admitted to hospital 1. Confirmation of Diagnosis Person with signs and symptoms suggesting heart failure Detailed history and clinical examination Consider aetiology for new diagnosis of heart Suspected diagnosis Confirmed failure or underlying cause for exacerbation of of heart failure diagnosis of heart chronic heart failure and exclude treatable Diagnosis has not failure causes. been confirmed by Diagnosis confirmed Arrange other investigations: echocardiogram by previous . CXR echocardiogram . ECG . FBC . U&Es and Creatinine . LFTs . TFTs . RBG . Cholesterol If current echocardiogram not Diagnosis confirmed by clinically relevant, echocardiogram, if possible Heart failure excluded so request repeat performed as an in-patient review diagnosis echo, if possible and adhering to Advancing performed as an in- Quality heart failure (AQHF) patient indicators Heart failure with preserved ejection Heart failure due to significant left ventricular fraction / diastolic dysfunction (EF systolic dysfunction (EF < 40%) >55%) • Update primary diagnosis on PCIS / -Update primary diagnosis on PCIS Cerner and document in casenotes /Cerner and document in casenotes. Proceed to Management of Confirmed Heart Failure Heart failure — managing newly diagnosed and decompensated patients in acute care — clinical guidelines, v1 Principal author: Dr P Saravanan Approved by Medicines Clinical Guideline Team: July 2013 Review by: July 2016 Page 1 of 27 2. Inpatient management Heart failure with preserved Heart failure due to left ventricular ejection fraction systolic dysfunction (EF < 40%) • Referral to heart failure specialist team. • Arrange admission to appropriate ward/unit Refer to Heart Failure Fluid balance: Drug management: Specialist Nurse for 1. Fluid restriction 1-2 litres in 24 1.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]